Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the presentation of ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announcedthat the company will present three ...

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) clinical data from ...

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients; Clinical benefit observed in 83% of eval ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...

Welcome to Vir Biotechnology's First Quarter 2025 Financial ... and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission ...